Orphan drugs to grow twice as fast as rest of the industry: report

Orphan drugs to grow twice as fast as rest of the industry: report

Research from EvaluatePharma predicts the orphan drug market will grow 11% each year to 2024.

Accenture faces 'conflict of interest' questions over buying programmatic, auditing media

Accenture faces 'conflict of interest' questions over buying programmatic, auditing media

Specialist media consulting firms and media agencies have claimed Accenture faces a "clear conflict" of interest over the launch of its programmatic media planning and buying unit.

Five things for pharma marketers to know: Friday, May 25, 2018

Five things for pharma marketers to know: Friday, May 25, 2018

AstraZeneca lung cancer drug meets key goal; Johnson & Johnson loses another talc lawsuit; Cancer drugs account for 80% of drug sales.

GDPR: How to make sure your business is ready

GDPR: How to make sure your business is ready

As of May 25, Europe's groundbreaking General Data Protection Regulation (GDPR) will take effect, fundamentally changing the way businesses and government agencies deal with personal data.

Analysts: J&J doesn't need to worry about Sun Pharma's prostate cancer drug

Analysts: J&J doesn't need to worry about Sun Pharma's prostate cancer drug

Sun Pharma's branded prostate cancer treatment Yonsa just received FDA approval.

VIDEO: Here's how Publicis Groupe's AI-powered Marcel will look and work

VIDEO: Here's how Publicis Groupe's AI-powered Marcel will look and work

Publicis Groupe unveiled its much-anticipated AI-powered platform Marcel at its VivaTech event this morning in Paris.

Five things for pharma marketers to know: Thursday, May 24, 2018

Five things for pharma marketers to know: Thursday, May 24, 2018

Recro non-opioid injection receives complete response letter from FDA; Pfizer settles False Claims Act allegations; Medtronic reports better-than-expected profit.

Experts skeptical feds' move on Insys will tilt scales of justice against opioid maker

Experts skeptical feds' move on Insys will tilt scales of justice against opioid maker

Insys founder John Kapoor has maintained his innocence in the face of charges.

How data regulation could be good for marketing post-Cambridge Analytica

How data regulation could be good for marketing post-Cambridge Analytica

Stuart Ingis on the benefits of showing the public how advertisers and marketers use data and creating a global regulatory framework.

4As O'Brien: How healthcare marketing has changed under Trump

4As O'Brien: How healthcare marketing has changed under Trump

Speakers at the Coalition for Healthcare Communication conference discussed how regulations from the White House and FDA have affected healthcare comms.